Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP3CSV)

Drug Name
AZD4604 Drug Info
Synonyms
JAK1-IN-7; AZD4604; 2241039-81-4; AZD-4604; JAC34RRR7S; (2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide; londamocitinib; UNII-JAC34RRR7S; CHEMBL4447181; SCHEMBL20399395; GTPL11716; BDBM488779; EX-A5343; US10961228, Example 35; AKOS040733485; AT39356; example 35 [WO2018134213A1]; MS-30607; HY-126294; CS-0101485; (R)-N-(3-(5-fluoro-2- (2-fluoro-3- (methylsulfonyl)phenyl amino)pyrimidin-4-yl)- 1H-indol-7-yl)-3- methoxy-2-(4- methylpiperazin-1- yl)propanamide; 1-Piperazineacetamide, N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1H-indol-7-yl)-alpha-(methoxymethyl)-4-methyl-, (alphaR)-
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 1 [1]
Cross-matching ID
PubChem CID
135240395
TTD Drug ID
DMP3CSV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Janus kinase 2 (JAK-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Momelotinib DMF98Q0 Myelofibrosis 2A20.2 Approved [3]
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [4]
Ruxolitinib DM7Q98D Essential thrombocythemia 3B63.1Z Approved [5]
Pacritinib DM1T6ZN Myelofibrosis 2A20.2 Approved [6]
Fedratinib DM4ZBK6 Myelofibrosis 2A20.2 Approved [7]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [8]
XL019 DMJ6F5C Solid tumour/cancer 2A00-2F9Z Phase 3 [8]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [9]
CTP-543 DM3SYOK Alopecia ED70 Phase 2 [10]
INCB039110 DMD9RV3 Malignant neoplasm 2A00-2F9Z Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Janus kinase 1 (JAK-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [4]
Ruxolitinib DM7Q98D Essential thrombocythemia 3B63.1Z Approved [5]
Upadacitinib DM32B5U Rheumatoid arthritis FA20 Approved [12]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [13]
SHR0302 DMUL8ZT Ulcerative colitis DD71 Phase 3 [14]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [15]
CTP-543 DM3SYOK Alopecia ED70 Phase 2 [10]
INCB039110 DMD9RV3 Malignant neoplasm 2A00-2F9Z Phase 2 [13]
PF-06700841 DMMGSFV Asthma CA23 Phase 2 [15]
ATI-501 DMTY6OF Alopecia ED70 Phase 2 [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Janus kinase 3 (JAK-3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tofacitinib DMBS370 Rheumatoid arthritis FA20 Approved [17]
Ritlecitinib DMYKNME Alopecia areata ED70.2 Approved [15]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [18]
VX-509 DM2U3MX Rheumatoid arthritis FA20 Phase 2/3 [4]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [15]
ATI-501 DMTY6OF Alopecia ED70 Phase 2 [16]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [19]
TD-8236 DMTOMJN Asthma CA23 Phase 2 [20]
ALXN2075 DM1BSD8 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [21]
SNA-125 DM8L1GJ Atopic dermatitis EA80 Phase 1 [15]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Inhibitor [2]
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Inhibitor [2]
Janus kinase 3 (JAK-3) TTT7PJU JAK3_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04769869) A Single-blind, Randomized, Placebo-controlled 3 Part Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 Following Single and Multiple Ascending Doses and to Investigate the Anti-inflammatory Effect of Inhaled AZD4604. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of AstraZeneca
3 Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4.
4 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
5 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
6 National Cancer Institute Drug Dictionary (drug id 609888).
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
8 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
9 Company report (Portola Pharmaceuticals)
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
14 Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Clinical pipeline report, company report or official report of Aclaris Therapeutics.
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
19 ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
20 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
21 The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.